LY01616

**LY01616** is an investigational fixed-dose compound liposome injection developed by Luye Pharma Group that co-encapsulates irinotecan hydrochloride and floxuridine at a defined synergistic ratio. The liposomal formulation is designed to maintain coordinated systemic exposure to both cytotoxic agents, thereby supporting synergistic antitumor activity while potentially shortening intravenous infusion time and reducing toxicity relative to conventional combination administration. It has entered a multicenter Phase I/II study in advanced solid tumors, with development focused particularly on advanced gastrointestinal cancers and colorectal cancer. ([luye.cn](https://www.luye.cn/lvye_en/view.php?id=1934))

Other names

Hydrochloride Irinotecan Floxuridine Compound Liposome InjectionIrinotecan Hydrochloride and Floxuridine Liposome Injection盐酸伊立替康氟脲苷脂质体注射液